BTIG analyst Julian Harrison reiterated a Buy rating on MoonLake Immunotherapeutics yesterday and set a price target of $30.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Julian Harrison has given his Buy rating due to a combination of factors tied to MoonLake Immunotherapeutics’ lead asset, SLK, and its regulatory progress in hidradenitis suppurativa. The FDA has agreed that the robust MIRA and VELA-1 trials together can provide the substantial evidence needed for approval, with MIRA’s best-in-class HiSCR75 results expected to be reflected directly in the product label, and VELA-TEEN supporting use in adolescents 12 years and older.
Julian Harrison’s rating is based on the clear and de-risked path to a BLA filing by the end of September 2026, with potential Priority Review and high historical approval rates in dermatology once filings are accepted. He also highlights upcoming readouts in HS and PsA that could expand SLK’s commercial opportunity beyond what is currently reflected in the stock, alongside a solid cash position projected to fund operations through 2027, and maintains an unchanged $30 price target reflecting his conviction in the risk‑reward profile.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $45.00 price target.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MLTX in relation to earlier this year.